Structure Therapeutics Inc.

NASDAQ:GPCR

Biotechnology

Healthcare
$17.36 +0.86%

+$0.39 today

Market cap
$999.36M
Beta
-1.42
P/E (TTM)
-19.3
EPS (TTM)
-$2.35
52W Low $15.80High $94.90

Volume 1.10M

Average 0.87M

GPCR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Structure Therapeutics Inc.NASDAQ: GPCR

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 72.65M shares rose 25.4% year over year, ahead of the +14.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +17.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.4% holds above the trailing-twelve-month pace of +14.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
72.65M+0.3% QoQ
Last fiscal yearDec 2025
59.2M+12.5% YoY
LTMJun 2026
65.7M+14.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.4%——
1 year+12.5%——
3-year CAGR+17.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
59.2M USD
Year-over-year change
+12.5%
4-year CAGR
+12.8%

Weighted Avg Shares (Diluted) vs competitors

How GPCR compares with its peers on the latest reported figures

  • GPCR's LTM Jun 2026 weighted avg shares (diluted) of 65.7M shares is the 3rd highest of the 8 companies compared; the peer median is 46.63M shares.
  • Its year-over-year change of +14.4% is the 4th highest of 7, against a peer median of +19.5%.
  • Over three fiscal years its annual growth of +17.4% compares with a peer median of +21.3%.
GPCR Competitors Peer median
Weighted Avg Shares (Diluted) for GPCR and competitors
Company Period LTM YoY 3-year CAGR
KLRAKailera Therapeutics, Inc.FY2025117.95M ——
MLYSMineralys Therapeutics, Inc.LTM Jun 202679.68M +45.9%+135.7%
GPCRStructure Therapeutics Inc.LTM Jun 202665.7M +14.4%+17.4%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.0%—
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
Peer median (excluding GPCR) 46.63M+19.5%+21.3%

Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00003.9M
Gross Profit0000(3.9M)
Gross Margin—————
Research & Development29.11M36.19M70.1M108.81M225.26M
Selling, General & Admin8.59M16.37M32.67M49.41M61.55M
Operating Expenses37.7M52.56M102.78M158.23M283.67M
Depreciation & Amortization72K277K295K992K3.9M
EBITDA(37.62M)(51.03M)(75.7M)(121.22M)(136.79M)
EBITDA Margin—————
Operating Income(37.7M)(52.56M)(102.78M)(158.23M)(287.57M)
Operating Margin—————
Interest Income1221.26M13.38M36.03M35.97M
Interest Expense122.16K013.39M00
Other Income / Expenses(122K)1.26M13.39M36.01M146.51M
Income Before Tax(37.82M)(51.3M)(89.38M)(122.22M)(140.69M)
Pre-Tax Margin—————
Income Tax Expense231K17K236K310K515K
Net Income(40.01M)(51.32M)(89.62M)(122.53M)(141.2M)
Net Margin—————
EPS (Basic)(1.20)(1.44)(2.43)(2.34)(2.40)
EPS (Diluted)(1.20)(1.44)(2.43)(2.34)(2.40)
Weighted Avg Shares36.59M36.59M36.73M52.64M59.2M
Weighted Avg Shares (Diluted)36.59M36.59M36.73M52.64M59.2M

Structure Therapeutics Inc.

NASDAQ:GPCR

Intrinsic Alpha fair value

Locked

Current Price

$17.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.